Two-dimensional gel analysis of human endometrial proteins: Characterization of proteins with increased expression in hyperplasia and adenocarcinoma

Molecular Human Reproduction

Volumn 5, Issue 8, 1999, Pages 748-756

  Byrjalsen, I ^a,d   Larsen, P Mose ^b   Fey, S J ^b   Nilas, L ^c   Larsen, M R ^c   Christiansen, C ^a  

^a CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

^d NORDIC BIOSCIENCE A S   (Denmark)

Author keywords

2 D gel electrophoresis; Cancer; Endometrium; Hyperplasia; Proteins

Indexed keywords

ENOLASE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; METHIONINE; PEPTIDE; PHOSPHOGLYCERATE KINASE; PROTEIN; REGULATOR PROTEIN; TRANSFERRIN; TROPOMYOSIN; VIMENTIN;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CLINICAL ARTICLE; DISEASE MARKER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; EXPLANT; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; ISOTOPE LABELING; PEPTIDE MAPPING; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEIN LOCALIZATION; SEQUENCE ANALYSIS; TWO DIMENSIONAL GEL ELECTROPHORESIS;

EID: 0345624495     PISSN: 13609947     EISSN: None     Source Type: Journal    
DOI: 10.1093/molehr/5.8.748     Document Type: Article

References (40)

1. Abeler, V.M. and Kjorsted, K.E. (1991) Endometrial adenocarcinoma in Norway. A study of a total population. Cancer, 67, 3093-3103.
2. Beck, E.P., Wagner, M., Anselmino, L. et al. (1997) Is OVX1 a suitable marker for endometrial cancer? Gynecol. Oncol., 65, 291-296.
3. Byrjalsen, I., Mose Larsen, P., Fey, S.J. et al. (1995a) Two-dimensional gel analysis of human endometrial proteins: cyclic changes in the expression of specific proteins during the normal menstrual cycle. Hum. Reprod., 10, 13-18.
4. Byrjalsen, I., Mose Larsen, P., Fey, S.J. et al. (1995b) Human endometrial proteins with cyclic changes in the expression during the normal menstrual cycle: characterization by protein sequence analysis. Hum. Reprod., 10, 2760-2766.
5. Ciocca, D.R., Oesterreich, S., Chamness, G.C. et al. (1993) Biological and clinical implications of heat shock protein 27 000 (Hsp27): a review. J. Natl. Cancer Inst., 85, 1558-1570.
6. Connelly, P.J., Alberhasky, R.C. and Christopherson, W.M. (1982) Carcinoma of the endometrium: III. Analysis of 865 cases of adenocarcinoma and adenoacanthoma. Obstet. Gynecol., 59, 569-575.
7. Creasman, W.T. (1993) Prognostic significance of hormone receptors in endometrial cancer. Cancer, 71 (Suppl. 4), 1467-1470.
8. Duk, J.M., Aalders, J.G., Fleuren, G.J. et al. (1986) CA125: A useful marker in endometrial adenocarcinoma. Am. J. Obstet. Gynecol., 155, 1097-1102.
9. Fey, S.J., Mose Larsen, P. and Biskjaer, N.L. (1984) In The Protein Variation in Basal Cells and certain Basal Cell Related Benign and Malignant Diseases. Prize Project, Faculty of Natural Science. Aarhus University, Denmark.
10. Gambrell, R.D. Jr. (1986) Prevention of endometrial cancer with progestogens. Maturitas, 8, 159-168.
11. Geisler, J.P., Geisler, H.E., Tammela, J. et al. (1999) A study of heat shock protein 27 in endometrial carcinoma. Gynecol. Oncol., 72, 347-350.
12. Gobom, J., Nordhoff, E., Ekman, R. et al. (1997) Rapid micro-scale proteolysis of proteins for MALDI-MS peptide mapping using immobilized trypsin. Int. J. Mass Spec. Ion. Proc., 169/170, 153-163.
13. Görg, A., Postel, W. and Günther, S. (1988) The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis, 9, 531-546.
14. Hammond, C.B., Jelovsek, F.R., Lee, K.L. et al. (1979) Effects on long-term estrogen replacement therapy. Neoplasia. Am. J. Obstet. Gynecol., 133, 537-547.
15. Jensen, O.N., Larsen, M.R. and Roepstorff, P. (1998) Mass spectrometric identification and microcharacterization of proteins from electrophoretic gels: strategies and applications. Proteins (Suppl. 2), 74-89.
16. Khalifa, M.A., Mannel, M.S., Haraway, S.D. et al. (1994) Expression of EFGR, HER-2/neu, P53, and PCNA in endometrioid. serous papillary, and clear cell endometrial adenocarcinomas. Gynecol. Oncol., 53, 84-92.
17. Mann, M., Højrup, P. and Roepstorff, P. (1993) Use of mass spectrometric molecular weight information to identify proteins in sequence databases. Biol. Mass Spectrom., 22, 338-345.
18. Nawrocki, A., Larsen, M.R., Podtelejnikov, A.V. et al. (1998) Correlation of acidic and basic carrier ampholyte and immobilized pH gradient two-dimensional gel electrophoresis patterns based on mass spectrometric protein identification. Electrophoresis, 19, 1024-1035.
19. Norwitz, E.R., Fernandez-Shaw, S., Barlow, D.H. et al. (1991) Expression of intermediate filament in endometrial glands changes with the onset of pregnancy and in endometriosis. Hum. Reprod., 6, 1470-1473.
20. Nyholm, H.C.J., Christensen, I.J. and Nielsen, A.L. (1995) Progesterone receptor levels independently predict survival in endometrial adenocarcinoma Gynecol. Oncol., 59, 347-351.
21. Nyholm, H.C.J. (1996) Estrogen and progesterone receptors in endometrial cancer. Clinipathological correlations and prognostic significance. A.P.M.I.S., 104 (Suppl. 65).
22. O'Farrell, P.H. (1975) High resolution two-dimensional electrophoresis of proteins. J. Biol. Chem., 250, 4007-4021.
23. Padwick, M.L., Whitehead, M. and King, R.J (1994) Hormonal regulation of HSP27 expression in human endometrial epithelial and stromal cells. Mol. Cell. Endocrinol., 102, 9-14.
24. Partridge, E.E., Shingleton, H.M. and Menck, H.R. (1996) The National Cancer Data Base report on endometrial cancer. J. Surg. Oncol., 61, 111-123.
25. Persson, I., Yuen, J., Bergkvist, L. et al. (1996) Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy -long-term follow-up of a Swedish cohort. Int. J. Cancer, 67, 327-332.
26. Rasty, G., Murray, R., Lu, L. et al. (1998) Expression of HER-2/neu oncogene in normal, hyperplastic and malignant endometrium. Ann. Clin. Lab. Sci., 28, 138-143.
27. Rosenfeld, J., Capdevielle, J., Guillemot, J.C. et al. (1992) In-gel digestion of proteins for internal sequence analysis after one-or two-dimensional gel electrophoresis. Anal. Biochem., 203, 173-179.
28. SAS Institute Inc. (1989) SAS/STAT® User's Guide, Version 6, Fourth Edn. Cary, NC: SAS Institute Inc.
29. Saegusa, M., Hashimura, M. and Okayasu, I. (1998) CD44 expression in normal, hyperplastic, and malignant endometrium. J. Pathol., 184, 297-306.
30. Scambia, G., Gadducci, A., Panici, P.B. et al. (1994) Combined use of CA 125 and CA 15-3 in patients with endometrial carcinoma. Gynecol. Oncol., 54, 292-297.
31. Shay, J.W. and Bachetti, S. (1997) A survey of telomerase activity in human cancer. Eur. J. Cancer. 33, 787-791.
32. Shevchenko, A., Wilm, M., Vorm, O. et al. (1996) Mass spectrometric sequencing of proteins from silver stained polyacrylamide gels. Anal. Biochem., 68, 850-858.
33. Shroyer, K.R., Stephens, J.K., Silverberg, S.G. et al. (1997) Telomerase expression in normal endometrium, endometrial hyperplasia, and endometrial adenocarcinoma. Int. J. Gynecol. Pathol., 16, 225-232.
34. Soong, R., Knowles, S., Williams, K.E. et al. (1996) Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Br. J. Cancer, 74, 562-567.
35. Tabibzadeh, S., Kong, Q.F., Satyaswaroop, P.G. et al. (1996) Heat shock proteins in human endometrium throughout the menstrual cycle. Hum. Reprod., 11, 633-640.
36. Takeshima, N., Shimuzu, Y., Umezawa, S. et al. (1994) Combined assay of serum levels of CA125 and CA19-9 in endometrial carcinoma. Gynecol. Oncol. 54, 321-326.
37. Tempfer, C., Haeusler, G., Kaider, A. et al. (1998) The prognostic value of CD44 isoform expression in endometrial cancer. Br. J. Cancer, 77, 1137-1139.
38. Xu, F.J., Yu, Y.H., Daly, L. et al. (1994) OVXI as a marker for early stage endometrial carcinoma. Cancer, 73, 1855-1858.
39. Yamanaka, M., Taga, M., and Minaguchi, H. (1996) Iinmunohistological localization of tenascin in the human endometrium. Gvnecol. Obstet. Invest., 41, 247-252.
40. Yokoyama, Y., Takahashi, Y., Shinohara, A. et al (1998) Telomerase activity in the female reproductive tract and neoplasms. Gynecol. Oncol., 68, 145-149.